Informed Consent and Alzheimer Disease Research: Institutional Review Board Policies and Practices
It is the nature of Alzheimer Disease (AD) that patients will suffer impaired memory, failure of the ability to reason, and loss of competency (Marson et al., 1994). Thus the question of whether or not AD patients may grant informed consent to participation in dementia research is a compelling consideration for clinical investigators as well as Institutional Review Boards (IRBs).
KeywordsAlzheimer Disease Alzheimer Disease Patient Associate Disorder Potential Therapeutic Benefit Proxy Consent
Unable to display preview. Download preview PDF.
- High DM, Whitehouse PJ, Post SG and Berg L (1994): Guidelines for addressing ethical and legal issues in Alzheimer Disease research. Alzheimer Disease and Associated Disorders 8 (Supp. 4):66.Google Scholar
- Kapp MB (1994): Proxy decision making in Alzheimer Disease research: durable powers of attorney, guardianship, and other alternatives. Alzheimer Disease and Associated Disorders 8 (Supp. 4):28.Google Scholar
- Moore DL (1994): An IRB member’s perspective on access to innovative therapy. Albany L Rev 57:559.Google Scholar
- Sachs GA (1994): Advance consent for dementia research. Alzheimer Disease and Associated Disorders 8 (Supp. 4):19.Google Scholar